Market Intelligence, Clinical Progress, and High-Purity Reagents for Multiple Myeloma Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLAMF7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLAMF7 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View SLAMF7 Products |
| Gene Delivery | SLAMF7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for ADCC/CDC target cell line construction. |
View SLAMF7 Products |
| Benchmark Ab | Anti-SLAMF7 (Sequence of Elotuzumab) Recombinant positive control. Sequence Verified. |
View SLAMF7 Products |
| Validator | SLAMF7 siRNA Set For knockdown verification in target-positive cell lines. |
View SLAMF7 Products |
| Related Target A | BCMA Co-expressed on plasma cells; primary target for combination therapy and bispecific/CAR-T profiling in Multiple Myeloma. |
View BCMA Products |
| Related Target B | CD38 Synergistic pathway target; co-targeting CD38 and SLAMF7 enhances MM cell clearance and NK cell activation. |
View CD38 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Soluble SLAMF7 (sSLAMF7) interference in serum | High-affinity HEK293-expressed ECD-Fc proteins with native glycosylation for robust competitive binding assays. |
| Subfamily off-target cross-reactivity (SLAMF1-6) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Lack of Controls | Clinical Benchmark Antibodies (Elotuzumab biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live SLAMF7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLAMF7 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies, ADCs, and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting dual-antigen engagement (e.g., SLAMF7 x CD3 bispecifics) and overcoming the immunosuppressive microenvironment in multiple myeloma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Bristol Myers Squibb, AbbVie | Multiple Myeloma (MM) | ADCC/CDC Assay validation (Need stable cell lines via Lentivirus) |
| Bispecific Antibody / T-cell Engager | Amgen, Roche | Relapsed/Refractory MM | Heterodimer Validation & Dual-affinity SPR (Need high-purity ECD-Fc proteins) |
| CAR-T Cell Therapy | Academic institutions, Biotech startups | Advanced Hematological Malignancies | Target density verification & CAR expression screening (Need sequence-verified antigens) |